ArticleBritish journal of cancer2005
Survivin, Survivin-2B, and Survivin-deItaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome.
Article in British journal of cancer, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01556178 (Collection of Blood and Cerebrospinal Fluid for Pediatric Brain Tumor Research), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Collection of Blood and Cerebrospinal Fluid for Pediatric Brain Tumor Research
Who cites it
30 citing papers in PubMed, 61 citations in OpenAlex.
- Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma.Cancer immunology, immunotherapy : CII · 2016Trial
- Therapeutic approaches for targeting the pediatric brain tumor microenvironment.Drug delivery and translational research · 2025Review
- Targeting the apoptosis pathway to treat tumours of the paediatric nervous system.Cell death & disease · 2022Review
- CD44 mediates stem cell mobilization to damaged lungInternational journal of medical sciences · 2020Article
- Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor.Journal of cancer research and clinical oncology · 2018Article
- Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma.Journal of neuro-oncology · 2015Article
- Suppressed diversity of survivin splicing in active rheumatoid arthritis.Arthritis research & therapy · 2015Article
- Article
- Survivin transcript variant 2 drives angiogenesis and malignant progression in proneural gliomas.Neuro-oncology · 2014Article
- Survivin expression in medulloblastoma: a possible marker for survival.Pathology oncology research : POR · 2013Article
- Targeting pediatric cancer stem cells with oncolytic virotherapy.Pediatric research · 2012Review
- Article
- Survivin splice variants are not essential for mitotic progression or inhibition of apoptosis induced by doxorubicin and radiation.OncoTargets and therapy · 2012Article
- Lack of prognostic significance of survivin in pediatric medulloblastoma.Pathology oncology research : POR · 2011Article
- Molecular interaction of Survivin and Piperine by computational docking analyses for neuroblastoma targeting.Annals of neurosciences · 2011Article
- Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors.Cancer immunology, immunotherapy : CII · 2010Review
- Survivin gene-expression and splicing isoforms in oral squamous cell carcinoma.Journal of cancer research and clinical oncology · 2009Article
- Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective.Neuro-oncology · 2008Review
- Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy.Journal of neuro-oncology · 2008Article
- Molecular docking and analysis of survivin delta-ex3 isoform protein.The open medicinal chemistry journal · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Survivin is an apoptotic inhibitor that is expressed at high levels in a variety of malignancies. Survivin has four known alternative splice forms (Survivin, Survivin-2B, Survivin-deltaEx3, and Survivin-3B), and the recent literature suggests that these splice variants have unique functions and subcellular localisation patterns. We evaluated 19 fresh-frozen paediatric medulloblastomas for the expression of three Survivin isoforms by quantitative PCR. Survivin was most highly expressed when compared with normal cerebellar tissue. We also investigated Survivin protein expression in 40 paraffin-embedded paediatric medulloblastoma tumours by immunohistochemistry. We found a statistically significant association between the percentage of Survivin-positive cells and histologic subtype, with the large-cell-anaplastic variant expressing Survivin at higher levels than the classic subtype. We also found a statistically significant relationship between the percent of Survivin-positive cells in the tumours and clinical outcome, with higher levels of Survivin correlating with a worse prognosis. In summary, our study demonstrates a role for Survivin as a marker of tumour morphology and clinical outcome in medulloblastoma. Survivin may be a promising future prognostic tool and potential biologic target in this malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.